- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04067063
Population Screening Using Smartphone in Milpa Alta (Smart-screen)
Massive Mental Health Screening Using Smartphone in Milpa Alta Community, Mexico.
The objective of this study is to make a suicide screening in the entire population of Milpa Alta (approximately 150,000 inhabitants), taking into account other outcomes such as depression, anxiety, alcohol and drugs. For this, an app for Smartphone (MeMind) or a web platform (www.MeMind.net) will be used in which the participants will take a self-administered questionnaire, composed of several psychometric instruments .
It is expected that 70% of the population between 15 and 70 years old can do so directly with their own Smartphone, although web access posts will be enabled in educational and municipal units to avoid discrimination based on age or access to technology.
Our main hypothesis argues that the early identification of people at risk in almost the entire community can be done with an App for Smartphone, serving to depict a map of mental health and related needs of the population, serving for the planning of healthcare services of the local environment, and ultimately for the best assistance of groups and individuals with greater needs through their identification and early reference to medical assistance.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Mexico City, Mexico, 12000
- Recruiting
- Alcaldía Milpa Alta. Ciudad de México
-
Contact:
- Pavel Arenas Castañeda
- Phone Number: +52-5586148610
- Email: arenaspavel@gmail.com
-
Principal Investigator:
- Enrique Baca-García, Dr
-
Principal Investigator:
- Fuensanta Aroca, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Use a smartphone as personal or computer terminals enabled by the municipality of Milpa Alta or educational services.
- Be able to understand the nature, purpose and methodology of the study.
- Accept participation in the study and check the corresponding box in the app to verify that the informed consent has been expressly given.
Exclusion Criteria:
- Subject deprived of liberty (by judicial or administrative decision)
- Subject protected by law (guardianship or conservatorship)
Study Plan
How is the study designed?
Design Details
- Observational Models: Ecologic or Community
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Milpa Alta inhabitants
Population among 15 and 70 years old
|
Smartphone app with MeMind questionnaires
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Suicidal ideation
Time Frame: 1 Day
|
Columbia-Suicide Severity Rating Scale (C-SSRS) is encompassed into MeMind for this purpose. In C-SSRS, four constructs are measured. The first is the severity of ideation, which is rated on a 5-point ordinal scale from 1="wish to be dead" to 5="suicidal intent with plan". The second is the intensity of ideation, which comprises 5 items, each rated on a 5-point ordinal scale: frequency, duration, controllability, deterrents, and reason for ideation. The third is the behavior, which is rated on a nominal scale that includes actual, aborted, and interrupted attempts; preparatory behavior; and nonsuicidal self-injurious behavior. And the fourth is the lethality, which assesses actual attempts; actual lethality is rated on a 6-point ordinal scale. Results are coded in the instrument itself with colored labels that indicates definitions of suicidal ideation and behavior, quantify both of them and gauge their severity. Definitions are available elsewhere (http://cssrs.columbia.edu). |
1 Day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depression
Time Frame: 1 Day
|
Participants will be asked to complete a questionnaire regarding possible symptoms related to depression. PHQ-9 questionnaire is emcompassed into Memind for this purpose. |
1 Day
|
Anxiety
Time Frame: 1 Day
|
Participants will be asked to complete a questionnaire regarding possible symptoms related to anxiety. GAD-7 (only screening questions) is emcompassed into Memind for this purpose. |
1 Day
|
Drug Utilization
Time Frame: 1 Day
|
Participants will be asked to complete a questionnaire regarding possible symptoms related to anxiety. DAST (only questions 1,6,7) is emcompassed into Memind for this purpose. |
1 Day
|
Alcohol Drinking
Time Frame: 1 Day
|
Participants will be asked to complete a questionnaire regarding possible symptoms related to alcohol abuse. Alcohol Use Disorders Identification Test (AUDIT-C) |
1 Day
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SmartMexSurvey1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
Clinical Trials on Self-administered evaluation questionnaire
-
Instituto de Investigación Sanitaria de la Fundación...Universidad Nacional Autonoma de Mexico; Instituciones Educativas de nivel... and other collaboratorsUnknownDepressive Disorder | Depression | Alcohol Drinking | Anxiety | Suicidal Ideation | Social Behavior | Drug AbuseMexico
-
International Longevity Centre FranceCompleted
-
Assistance Publique - Hôpitaux de ParisPr Joel COSTE, Hôpital Hôtel Dieu - Unité de Bio Statistiques et Epidémiologiques...CompletedCOPD (With - Without Rehabilitation) | Diffuse Interstitial Lung Diseases | Pulmonary Arterial Hypertension Primary or Secondary (Post Embolic .....) | Cystic Fibrosis of the AdultFrance
-
University Hospital, LilleFondation Santé RoquetteCompleted
-
University Hospital, LilleFondation Santé RoquetteUnknown
-
Alaa Mohammed YehiaCompletedMolar Incisor Hypomineralization | Dental Enamel HypoplasiaEgypt
-
Central Hospital, Nancy, FranceCompletedAtopic DermatitisFrance
-
University Hospital, BordeauxRecruitingInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisFrance
-
Centre Hospitalier Charles Perrens, BordeauxRégion Nouvelle Aquitaine; Regional Health Agency New AquitaineNot yet recruitingCovid19 | Work-Related Condition | Work-Related Stress Disorder | Personnel, Hospital
-
University Hospital, MontpellierTerminated